Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
To date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/5/1203 |
id |
doaj-8947104363fd421c8292bf09e3a84694 |
---|---|
record_format |
Article |
spelling |
doaj-8947104363fd421c8292bf09e3a846942021-06-01T00:01:27ZengMDPI AGCells2073-44092021-05-01101203120310.3390/cells10051203Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?Elia Bari0Ilaria Ferrarotti1Laura Saracino2Sara Perteghella3Maria Luisa Torre4Luca Richeldi5Angelo Guido Corsico6Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, ItalyCenter for Diagnosis of Inherited Alpha1-Antitrypsin Deficiency, Department of Internal Medicine and Therapeutics, Pneumology Unit IRCCS San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, ItalyPneumology Unit IRCCS San Matteo Hospital Foundation, 27100 Pavia, ItalyDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, ItalyDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, ItalyComplex Operative Unit of Pneumology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, 00168 Rome, ItalyCenter for Diagnosis of Inherited Alpha1-Antitrypsin Deficiency, Department of Internal Medicine and Therapeutics, Pneumology Unit IRCCS San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, ItalyTo date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent to design a strategy to prevent a second wave of late mortality associated with COVID-19 PF as a long-term consequence of such a devastating pandemic. Available antifibrotic therapies, namely nintedanib and pirfenidone, might have a role in attenuating profibrotic pathways in SARS-CoV-2 infection but are not economically sustainable by national health systems and have critical adverse effects. It is our opinion that the mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 fibrotic lungs through its anti-inflammatory and antifibrotic factors.https://www.mdpi.com/2073-4409/10/5/1203SARS-CoV-2COVID-19pulmonary fibrosismesenchymal stem cellsextracellular vesiclesmicrovesicles |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elia Bari Ilaria Ferrarotti Laura Saracino Sara Perteghella Maria Luisa Torre Luca Richeldi Angelo Guido Corsico |
spellingShingle |
Elia Bari Ilaria Ferrarotti Laura Saracino Sara Perteghella Maria Luisa Torre Luca Richeldi Angelo Guido Corsico Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? Cells SARS-CoV-2 COVID-19 pulmonary fibrosis mesenchymal stem cells extracellular vesicles microvesicles |
author_facet |
Elia Bari Ilaria Ferrarotti Laura Saracino Sara Perteghella Maria Luisa Torre Luca Richeldi Angelo Guido Corsico |
author_sort |
Elia Bari |
title |
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? |
title_short |
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? |
title_full |
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? |
title_fullStr |
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? |
title_full_unstemmed |
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? |
title_sort |
mesenchymal stromal cell secretome for post-covid-19 pulmonary fibrosis: a new therapy to treat the long-term lung sequelae? |
publisher |
MDPI AG |
series |
Cells |
issn |
2073-4409 |
publishDate |
2021-05-01 |
description |
To date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent to design a strategy to prevent a second wave of late mortality associated with COVID-19 PF as a long-term consequence of such a devastating pandemic. Available antifibrotic therapies, namely nintedanib and pirfenidone, might have a role in attenuating profibrotic pathways in SARS-CoV-2 infection but are not economically sustainable by national health systems and have critical adverse effects. It is our opinion that the mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 fibrotic lungs through its anti-inflammatory and antifibrotic factors. |
topic |
SARS-CoV-2 COVID-19 pulmonary fibrosis mesenchymal stem cells extracellular vesicles microvesicles |
url |
https://www.mdpi.com/2073-4409/10/5/1203 |
work_keys_str_mv |
AT eliabari mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae AT ilariaferrarotti mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae AT laurasaracino mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae AT saraperteghella mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae AT marialuisatorre mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae AT lucaricheldi mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae AT angeloguidocorsico mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae |
_version_ |
1721416013870792704 |